162 related articles for article (PubMed ID: 19212214)
61. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
[TBL] [Abstract][Full Text] [Related]
62. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
63. Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms.
Dong B; Zhang Y; Fu X; Wang G
Thromb Res; 2012 May; 129(5):664-5. PubMed ID: 22197451
[No Abstract] [Full Text] [Related]
64. Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders.
Lieu CH; Wu HS; Hon YC; Tsai WH; Yang CF; Wang CC; Lin YC; Shih CH; Hsu HC
Intern Med J; 2008 Jun; 38(6):422-6. PubMed ID: 18336541
[TBL] [Abstract][Full Text] [Related]
65. Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis.
Saugel B; Lee M; Feichtinger S; Hapfelmeier A; Schmid RM; Siveke JT
J Thromb Thrombolysis; 2015 Jul; 40(1):54-60. PubMed ID: 25115839
[TBL] [Abstract][Full Text] [Related]
66. The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group.
Schwarz J; Penka M; Indrák K; Pospísilová D; Pytlík R; Dulícek P; Doubek M; Kren L; Campr V;
Leukemia; 2008 Nov; 22(11):2118-9. PubMed ID: 18418405
[No Abstract] [Full Text] [Related]
67. [The frequency of JAK2 V617F mutation, expression level of phosphorylated JAK/STATs proteins and their clinical significance in myeloproliferative disorders patients].
Hu GY; Deng MY; Zhang GS; Luo YY; Zhu JF
Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):394-8. PubMed ID: 19951533
[TBL] [Abstract][Full Text] [Related]
68. [Portal vein thrombosis].
Seijo-Ríos S; García-Pagán JC
Gastroenterol Hepatol; 2010 Mar; 33(3):179-90. PubMed ID: 19733938
[TBL] [Abstract][Full Text] [Related]
69. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
70. Comparison of JAK2 V617F burden quantitation by two different quantitative-polymerase chain reaction methods.
Le Bars H; Boulland ML; Bareau B; Grosbois B; Corolleur M; Lamy T; Fardel O
Int J Lab Hematol; 2010 Aug; 32(4):458-60. PubMed ID: 20331762
[No Abstract] [Full Text] [Related]
71. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
72. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.
Qi X; Yang Z; Bai M; Shi X; Han G; Fan D
Aliment Pharmacol Ther; 2011 May; 33(10):1087-103. PubMed ID: 21395632
[TBL] [Abstract][Full Text] [Related]
73. JAK2V617F mutation in patients with portal vein thrombosis.
Bayraktar Y; Harmanci O; Büyükasik Y; Shorbagi AI; Sungur AH; Boylu CA; Gürgey A; Balkanci F
Dig Dis Sci; 2008 Oct; 53(10):2778-83. PubMed ID: 18343999
[TBL] [Abstract][Full Text] [Related]
74. Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis.
Iurlo A; Cattaneo D; Gianelli U; Fermo E; Augello C; Cortelezzi A
Ann Hematol; 2015 May; 94(5):881-2. PubMed ID: 25377046
[No Abstract] [Full Text] [Related]
75. Primary thrombophilia in México VII: the V617F mutation of JAK2 is not a frequent cause of thrombosis.
Garcés-Eisele J; González-Carrillo ML; Reyes-Núñez V; Ruiz-Argüelles GJ
Hematology; 2008 Aug; 13(4):244-6. PubMed ID: 18796251
[TBL] [Abstract][Full Text] [Related]
76. Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.
Morsia E; Torre E; Martini F; Morè S; Poloni A; Olivieri A; Rupoli S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338802
[TBL] [Abstract][Full Text] [Related]
77. The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.
Goodyer M; Langabeer SE; Haslam K; Murphy K
Pathol Oncol Res; 2016 Jan; 22(1):229-30. PubMed ID: 26450123
[No Abstract] [Full Text] [Related]
78. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies.
Kiladjian JJ; Cassinat B
Am J Hematol; 2023 May; 98(5):794-800. PubMed ID: 36869873
[TBL] [Abstract][Full Text] [Related]
79. Extrahepatic portal vein obstruction and portal vein thrombosis in special situations: Need for a new classification.
Wani ZA; Bhat RA; Bhadoria AS; Maiwall R
Saudi J Gastroenterol; 2015; 21(3):129-38. PubMed ID: 26021771
[TBL] [Abstract][Full Text] [Related]
80. Chronic lymphocytic leukemia presenting as an intracranial epidural mass in a patient with myeloproliferative neoplasm associated with JAK2 V617F mutation.
Chan KL; McKelvie P; Firkin F; Bazargan A; Tam CS
Leuk Lymphoma; 2013 May; 54(5):1110-2. PubMed ID: 23088192
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
